Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 38.1% in December

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 110,600 shares, a decline of 38.1% from the November 30th total of 178,800 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 83,200 shares, the days-to-cover ratio is presently 1.3 days.

Aileron Therapeutics Price Performance

Shares of Aileron Therapeutics stock opened at $2.25 on Friday. The business has a fifty day simple moving average of $2.92 and a two-hundred day simple moving average of $2.88. Aileron Therapeutics has a 1 year low of $1.61 and a 1 year high of $7.42. The company has a market capitalization of $48.75 million, a price-to-earnings ratio of -0.72 and a beta of 2.23.

Institutional Trading of Aileron Therapeutics

Hedge funds have recently modified their holdings of the stock. University of Texas Texas AM Investment Management Co. acquired a new stake in Aileron Therapeutics during the second quarter worth approximately $4,925,000. Warberg Asset Management LLC bought a new position in shares of Aileron Therapeutics during the second quarter worth approximately $86,000. Nantahala Capital Management LLC boosted its stake in Aileron Therapeutics by 82.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after purchasing an additional 209,367 shares during the period. KG&L Capital Management LLC acquired a new position in Aileron Therapeutics in the 3rd quarter valued at $46,000. Finally, Sigma Planning Corp increased its position in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after buying an additional 86,185 shares during the period. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).